Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy

Approval is based on the Phase 3 KEYNOTE-868/NRG-GY018 Trial

KIRKLAND, QC, March 19, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA^® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA^® as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvements in progression-free survival (PFS) for patients randomized to KEYTRUDA^® in combination with chemotherapy compared to placebo in combination with chemotherapy in both the deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) populations.